IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.69
+1.85%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
Market Cap
$389.77M
MomentumView details →
1D Return
+1.85%
YTD Return
+127.60%
RSI (14)
66.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
Market Cap
$389.77M
RSI (14)
66.9
MomentumView details →
1D Return
+1.85%
YTD Return
+127.60%
SummaryUpdated Jun 1, 2026
Opus Genetics, Inc. (NASDAQ:IRD) is a clinical-stage ophthalmic biopharmaceutical company founded in 2018 and headquartered in Farmington Hills, Michigan. Originally known as Ocuphire Pharma, Inc., the company went public in 2015 and focuses on developing innovative therapies for patients with refractive and retinal eye disorders. The company operates in the specialized field of ophthalmology, targeting unmet medical needs in eye care through both commercially available products and an active clinical development pipeline.
Similar companies
Latest newsMore news →